New peritoneal dialysis diagnostic discovered

Oct 17, 2007

Thanks to a discovery by scientists at Robarts Research Institute and The University of Western Ontario, patients undergoing peritoneal dialysis may soon be able to worry less about the risks of infection and lessen their hospital stays.

Peritoneal dialysis, which involves placing a tube into the peritoneal cavity, allows people who have suffered from kidney failure to carry on a relatively normal life; however, complications include high incidence of infection of the abdominal cavity, known as peritonitis, which most patients experience every year or so.

Led by Joaquin Madrenas, Robarts scientist and Canada Research Chair in Immunobiology at Western, the study has looked at the molecule RIP2 (receptor-interacting protein 2) for clues over the past three years. Though the precise function of RIP2 is not yet known, scientists made the important finding that levels of the molecule increase during infection. More importantly, peritoneal dialysis patients with peritonitis who have high levels of RIP2 can be sent home and treated with antibiotics. If RIP2 levels do not go up, patients risk a protracted infection and should be admitted for closer monitoring and more intense treatment. This information can be used to address the need to admit patients to the hospital.

“We currently have no objective indicator if peritonitis will be really bad, so we tend to try to guess how bad it is,” says Madrenas. “What we have found is that, by monitoring RIP2, we can predict the outcome of the infection in patients taking part in peritoneal dialysis.”

By keeping patients out of hospitals, this discovery not only helps improve quality of life, but also reduces strain on the healthcare system.

The team, which includes Madrenas’ PhD student Michelle McCully and a close collaboration with Dr. Peter Blake of the division of nephrology at Western, will now try to adapt the discovery to a clinical laboratory and hopefully develop a diagnostic test that can be conducted with a patient’s peritoneal fluid on a routine basis. Madrenas also wonders if there are other factors preventing RIP2 levels from increasing in some patients. “If we know what problem is preventing this increase, we could fix it and possibly prevent infections,” he says.

Source: University of Western Ontario

Explore further: The first UK medical school launches Google Glass technology in curriculum

add to favorites email to friend print save as pdf

Related Stories

Will Apple Pay be mobile pay's kick-start?

6 hours ago

If anyone can get us to use our smartphones as wallets, it's Apple. That's what experts think about the recent launch of Apple Pay, the first mobile wallet to work on an iPhone.

Google execs discuss regulation, innovation and bobble-heads

7 hours ago

Eric Schmidt and Jonathan Rosenberg help run Google, one of the world's best-known, most successful - and most controversial - companies. They've just published a new book, "How Google Works," a guide to managing what they ...

Developing the battery of the future

8 hours ago

The search for the next generation of batteries has led researchers at the Canadian Light Source synchrotron to try new methods and materials that could lead to the development of safer, cheaper, more powerful, ...

Gamers' funding fuels meteoric rise of 'Star Citizen'

8 hours ago

Chris Roberts' brain spun out a grand vision: a rich, immersive galaxy; exquisite spaceships traversing between infinite star systems with thousands of computer gamers manning the cockpits, racing, dogfighting and defending ...

Recommended for you

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.